Human Metabolome Technologies (TSE:6090) Cyclically Adjusted Revenue per Share: 円0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6090 Human Metabolome Technologies Inc TSE:6090
59 GF Score
Price 円599.00
GF Value 円531.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Cyclically Adjusted Revenue per Share?

Human Metabolome Technologies TSE:6090 +0.67% 59 Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円531.46 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Human Metabolome Technologies's adjusted revenue per share for the three months ended in Dec. 2025 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-03), Human Metabolome Technologies's current stock price is 円599.00. Human Metabolome Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was 円0.00. Human Metabolome Technologies's Cyclically Adjusted PS Ratio of today is .

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Human Metabolome Technologies was 4.19. The lowest was 2.92. And the median was 3.44.


Human Metabolome Technologies  (TSE:6090) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Human Metabolome Technologies was 4.19. The lowest was 2.92. And the median was 3.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Human Metabolome Technologies Cyclically Adjusted Revenue per Share Related Terms


Human Metabolome Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Cyclically Adjusted Revenue per Share Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 180.57 193.28

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.16 205.14 207.24 0.00 0.00

TSE:6090 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Human Metabolome Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Human Metabolome Technologies Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Human Metabolome Technologies's Cyclically Adjusted PS Ratio falls into.


TSE:6090
59GF Score
Human Metabolome Technologies Inc TSE:6090
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Human Metabolome Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Human Metabolome Technologies's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Human Metabolome Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 28.366 98.100 32.674
201603 61.798 97.900 71.330
201606 17.166 98.100 19.773
201609 31.175 98.000 35.947
201612 40.835 98.400 46.894
201703 69.556 98.100 80.121
201706 20.232 98.500 23.210
201709 32.665 98.800 37.360
201712 36.493 99.400 41.486
201803 71.744 99.200 81.725
201806 25.842 99.200 29.437
201809 21.461 99.900 24.275
201812 27.727 99.700 31.426
201903 67.588 99.700 76.604
201906 0.000 99.800 0.000
201909 33.883 100.100 38.250
201912 43.731 100.500 49.170
202003 91.816 100.300 103.442
202006 21.242 99.900 24.027
202009 41.675 99.900 47.140
202012 49.478 99.300 56.304
202103 65.931 99.900 74.577
202106 33.485 99.500 38.028
202109 29.411 100.100 33.201
202112 61.046 100.100 68.913
202203 80.744 101.100 90.248
202206 36.117 101.800 40.091
202209 44.489 103.100 48.761
202212 58.917 104.100 63.954
202303 78.682 104.400 85.163
202306 37.912 105.200 40.723
202309 39.824 106.200 42.374
202312 67.218 106.800 71.120
202403 81.585 107.200 85.999
202406 38.897 108.200 40.623
202412 0.000 110.700 0.000
202503 98.509 111.100 100.194
202506 32.123 111.700 32.497
202509 33.863 112.000 34.165
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
Human Metabolome Technologies (TSE:6090) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Human Metabolome Technologies and its competitors.
Is Human Metabolome Technologies' Cyclically Adjusted Revenue per Share too high?
Human Metabolome Technologies' current Cyclically Adjusted Revenue per Share is 円0.00. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Human Metabolome Technologies' Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円531.46, compared to a current price of 円599.00 — trading 12.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued. The current stock price of 円599.00 is trading 12.7% above its estimated GF Value™ of 円531.46. GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.

Key valuation signals for TSE:6090:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円531.46 vs. price of 円599.00 (12.7% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
59GF Score

Get the complete analysis for TSE:6090

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円599.00
Price
円531.46
GF Value